Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19

NCT07445971 is registered in ClinicalTrials.gov with ModeX Therapeutics, An OPKO Health Company as lead sponsor.

NCT NCT07445971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07445971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19
Lead sponsor
ModeX Therapeutics, An OPKO Health Company
Phase
Phase 1
Overall status
Recruiting
Start date
March 24, 2026
Completion date
December 31, 2027
Enrollment
80 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid -19, covid-19 (prevention)